As per MRFR analysis, the South America Onychomycosis Market Size was estimated at 398 (USD Million) in 2023. The South America Onychomycosis Market Industry is expected to grow from 417(USD Million) in 2024 to 706.7 (USD Million) by 2035. The South America Onychomycosis Market CAGR (growth rate) is expected to be around 4.912% during the forecast period (2025 - 2035)
Key South America Onychomycosis Market Trends Highlighted
In the South America Onychomycosis Market, key market drivers include the increasing prevalence of fungal infections and rising awareness about foot health among the population. The region experiences favorable climatic conditions that contribute to the spread of these infections, especially in humid areas like the Amazon basin. Additionally, the growing geriatric population is more susceptible to onychomycosis, further driving market growth. Opportunities to be explored include the development of affordable and effective antifungal treatments that cater to different demographic needs. Local pharmaceutical companies are focusing on creating specialized medications aimed at treating fungal nail infections, reflecting an untapped market potential.
In South America, there has been a distinct movement toward innovative diagnostic applications and telemedicine practices. Technology is making it possible to obtain treatment and improve patient results. Health authority educational campaigns are improving knowledge about onychomycosis's persistent issue and its prevalent treatment ways, thus increasing the demand for therapy region-wide. Furthermore, the shift towards natural and organic products is also gaining attention as it's safer and less toxic instead of being used on children. The use of standard treatment guidelines is encouraged by the region’s governing bodies, which might assist in meeting the regional health demands through the acquisition of new products and their enhanced treatment efficaciousness.
As a result, these trends signal a growing interest in innovative and effective solutions for onychomycosis treatment in South America, paving the way for substantial industry advancements.
Source: Primary Research, Secondary Research, MRFR Database and Analyst Review
South America Onychomycosis Market Drivers
Rising Incidence of Onychomycosis in South America
The South America Onychomycosis Market Industry is experiencing significant growth due to the increasing incidence of onychomycosis, a fungal infection affecting the nails. Recent health reports indicate that dermatological issues, including fungal infections, are on the rise in various South American countries. For instance, Brazil's National Health System has noted a 40% increase in cases of dermatophytic infections, including onychomycosis, over the last decade.As public health agencies and dermatology associations work to address the prevalence of these infections, the demand for effective treatment options is expected to grow.
Institutes like the Brazilian Society of Dermatology actively promote awareness and provide treatment guidelines, thereby fostering growth in the South America Onychomycosis Market. The escalating rate of onychomycosis treatments and products, such as topical antifungals and laser therapies, further solidifies the market's potential in South America, thereby projecting considerable revenue growth in the coming years.
Increased Awareness and Diagnosis of Fungal Infections
The South America Onychomycosis Market Industry is also being driven by heightened awareness and improved diagnosis of fungal infections. Initiatives led by organizations such as the Brazilian Ministry of Health have focused on infectious diseases improving education regarding dermatological conditions. Recently, the agency reported that public awareness campaigns have increased dermatological visits by 25% in urban centers.
With better diagnostic tools and training for healthcare professionals, the rate of diagnosed cases of onychomycosis is set to rise.As more patients seek treatment and education is enhanced, manufacturers can anticipate an uptick in demand for onychomycosis treatment products and services in the South America Onychomycosis Market, contributing to its overall growth.
Aging Population in South America
The demographic shift towards an aging population in South America plays a crucial role in the growth of the South America Onychomycosis Market Industry. According to the Economic Commission for Latin America and the Caribbean, the percentage of individuals over 60 years old is projected to rise significantly, from 10% currently to 20% by 2030. This age group is more susceptible to various health issues, including onychomycosis, due to weakened immunity and other health-related factors.
As elder care and geriatric healthcare become more prioritized in policies across South American nations, there will be an inherent increase in the focus on treating onychomycosis among older adults. Consequently, this demographic trend is expected to lead to greater market opportunities for suppliers of onychomycosis treatments in the region.
South America Onychomycosis Market Segment Insights
Onychomycosis Market Type Insights
The South America Onychomycosis Market is primarily segmented by type, focusing on various forms of nail fungal infections that are prevalent in the region. Distal Subungual Onychomycosis stands out as a significant type, characterized by its higher incidence and more challenging treatment options, which exacerbates its clinical importance in South America. White Superficial Onychomycosis, while less common, garners attention due to its visible nature that can prompt earlier diagnosis and treatment among individuals. Additionally, Proximal Subungual Onychomycosis, often associated with immunocompromised patients, raises awareness of the link between systemic health issues and nail infections.
Candida Onychomycosis also plays a critical role, particularly in tropical areas of South America, where higher humidity can facilitate fungal growth, making it an important area for treatment and market development. The category of "Others" captures various less common fungal infections that still contribute to the overall burden of onychomycosis in this region. Overall, the landscape of the South America Onychomycosis Market segmentation by type highlights the diverse challenges presented by different fungal infections, driving the need for tailored treatment approaches and fostering growth opportunities for pharmaceutical companies focused on this niche yet significant market.
As public awareness of skin health rises in South America, the demand for effective treatments will likely continue to grow, presenting both opportunities and challenges for stakeholders within the South America Onychomycosis Market. Furthermore, significant public health campaigns aimed at educating the population about fungal infections and promoting early treatment could enhance engagement in addressing this prevalent condition across the region.
Source: Primary Research, Secondary Research, MRFR Database and Analyst Review
Onychomycosis Market Treatment Type Insights
The Treatment Type segment of the South America Onychomycosis Market encompasses various methods aimed at effectively tackling fungal nail infections. This segment includes Drug Treatment, Topical Therapy, and other treatment options, all of which play critical roles in addressing this common condition. Drug Treatment is crucial as it often provides systemic solutions, making it effective for more severe infections that do not respond to surface therapies. Topical Therapy, on the other hand, remains significant due to its non-invasive nature and convenience for patients, making it a preferred choice for mild cases.
Other therapies include oral medications and potential new methodologies, which are gaining traction as advances in treatment options proliferate. The rising awareness of foot health and increasing incidences of nail fungi in humid climates prevalent in South America are contributing factors to the market's expansion. Overall, the increasing focus on effective and accessible treatment options is expected to shape the dynamics within the South America Onychomycosis Market, driving satisfactory outcomes for both patients and healthcare providers alike.
Onychomycosis Market End Users Insights
The South America Onychomycosis Market showcases diverse End Users that play crucial roles in the distribution and accessibility of treatments. Hospital pharmacies have emerged as vital players due to their capability to provide tailored medical solutions and a broader range of antifungal formulations, thereby enhancing patient outcomes. Retail pharmacies possess a significant presence in the market, offering convenient access to over-the-counter products and increasing awareness of onychomycosis among the general public, which drives product demand.
The Others segment, encompassing online pharmacies and alternative health outlets, taps into the growing trend of digital healthcare, reflecting shifts in consumer behavior towards online purchasing and consultation. This diversity within the End Users highlights the variable pathways through which patients access treatments, influenced by factors such as convenience, medical advice, and cultural attitudes toward healthcare in South America. Overall, the segmentation among End Users contributes to the market growth by ensuring that treatments are available in various formats and settings, aligning with regional healthcare challenges and consumer preferences.The trends within these segments suggest an ongoing evolution in response to the growing prevalence of onychomycosis and increasing awareness in South America, ultimately influencing the South America Onychomycosis Market data significantly.
Onychomycosis Market Regional Insights
The South America Onychomycosis Market is characterized by its diverse regional segmentation, primarily including Brazil, Mexico, Argentina, and the Rest of South America. Brazil holds a substantial share of the market due to its large population and rising awareness about fungal infections that affect nail health. Mexico follows, with a significant market contribution fueled by an increasing incidence rate of onychomycosis along with a growing focus on personal health and hygiene. Argentina also plays a notable role in the market, driven by a rising healthcare infrastructure and access to better treatment options.The Rest of South America includes various countries where awareness and treatment options are gradually improving, contributing to overall market growth.
The collective demand for antifungal treatments and supportive healthcare services in these regions indicates a promising future for the South America Onychomycosis Market, propelled by increasing population health consciousness and ongoing healthcare advancements. Additionally, regional healthcare initiatives and investment in dermatological therapies present further opportunities for market expansion across South America.
Source: Primary Research, Secondary Research, MRFR Database and Analyst Review
South America Onychomycosis Market Key Players and Competitive Insights:
The South America Onychomycosis Market has been witnessing significant growth attributed to the rising prevalence of fungal nail infections, increasing awareness among the population about the disease, and an expanding range of treatment options available in the region. The competitive landscape is characterized by a mix of global and regional players vying for market share through innovative product offerings and robust marketing strategies. The competition is intensified further due to the evolving regulatory landscape, which encourages companies to develop effective and safe therapeutic solutions.
As the market matures, focus on advanced drug formulations and delivery systems becomes paramount, leading to increased investments and research and development efforts. Amgen has established a notable presence in the South America Onychomycosis Market through its innovative product portfolio and extensive distribution networks. The company is recognized for its commitment to research in fungal infections and its ability to offer effective treatment options tailored toward patient needs.
One of the key strengths of Amgen lies in its well-established reputation for high-quality pharmaceutical products, along with its strong relationships with healthcare professionals that enhance its market positioning. Their strategic marketing approaches and localized training programs for medical representatives further ensure that the onychomycosis treatment options are well-promoted and accessible across various regions in South America. GSK plays a significant role in the South America Onychomycosis Market, providing a comprehensive range of antifungal medications that cater to diverse patient demographics. The strength of GSK’s market presence is bolstered by its well-researched product pipeline and focus on patient compliance, leading to effective outcomes in onychomycosis treatment.
GSK has also pursued strategic mergers and acquisitions in the region to enhance its portfolio and distribution capabilities, which has markedly improved its reach in South America. Among its key products, GSK focuses on topical treatments and systemic therapies aimed at addressing the specific needs of patients suffering from fungal infections. The company’s strong emphasis on community engagement and collaboration with local healthcare providers ensures that its products are effectively integrated into treatment regimes, further solidifying its competitive advantage in the market.
Key Companies in the South America Onychomycosis Market Include
South America Onychomycosis Market Industry Developments
The South America Onychomycosis Market has seen several developments recently. In October 2023, Amgen received approval for a new topical treatment specifically targeting onychomycosis, which is expected to enhance its market presence. Additionally, GSK launched a public awareness campaign across Brazil, aiming to educate patients about fungal nail infections and the importance of seeking treatment. In July 2023, Bayer and Galderma announced an agreement to collaborate on joint clinical trials, combining their efforts to advance therapy options for onychomycosis, showcasing a commitment to Research and Development in this field.
The market has experienced valuation growth, driven by rising awareness and demand for effective treatments, specifically in urban areas of South America. Moreover, in January 2022, AbbVie expanded its product line for dermatological conditions in Argentina, further indicating the increasing focus on addressing fungal infections, including onychomycosis. The competitive landscape remains robust, with strong efforts from Merck and Pfizer to introduce innovative therapies. Overall, market dynamics depict a trend towards enhanced treatment availability, fueled by ongoing Research and Development and collaborative initiatives among key players.
South America Onychomycosis Market Segmentation Insights
Onychomycosis Market Type Outlook
Onychomycosis Market Treatment Type Outlook
Onychomycosis Market End Users Outlook
Onychomycosis Market Regional Outlook
| Report Attribute/Metric Source: | Details |
| MARKET SIZE 2023 | 398.0(USD Million) |
| MARKET SIZE 2024 | 417.0(USD Million) |
| MARKET SIZE 2035 | 706.7(USD Million) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 4.912% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| MARKET FORECAST PERIOD | 2025 - 2035 |
| HISTORICAL DATA | 2019 - 2024 |
| MARKET FORECAST UNITS | USD Million |
| KEY COMPANIES PROFILED | Amgen, GSK, Bayer, Galderma, AbbVie, Teva, Eli Lilly, Astellas, Merck, Sanofi, Incyte, Novartis, Johnson & Johnson, Pfizer |
| SEGMENTS COVERED | Type, Treatment Type, End Users, Regional |
| KEY MARKET OPPORTUNITIES | Increasing prevalence of fungal infections, Growing geriatric population, Rising awareness about treatment options, Development of novel therapies, Expansion of telemedicine services |
| KEY MARKET DYNAMICS | rising prevalence of fungal infections, increasing aging population, growing awareness of treatment options, expanding healthcare infrastructure, demand for effective antifungal therapies |
| COUNTRIES COVERED | Brazil, Mexico, Argentina, Rest of South America |
Frequently Asked Questions (FAQ) :
The South America Onychomycosis Market is expected to be valued at 417.0 million USD in 2024.
By 2035, the market is projected to reach a value of 706.7 million USD.
The expected CAGR for the South America Onychomycosis Market from 2025 to 2035 is 4.912%.
Brazil is expected to hold the largest market share, valued at 150.0 million USD in 2024.
Argentina's market for Onychomycosis is valued at 80.0 million USD in 2024.
Major players in the South America Onychomycosis Market include Amgen, GSK, Bayer, and Galderma.
The market for Distal Subungual Onychomycosis is expected to reach 255.0 million USD by 2035.
The White Superficial Onychomycosis segment is valued at 90.0 million USD in 2024.
Challenges in the South America Onychomycosis Market include increasing competition and varied regulatory environments.
The market for the Rest of South America is anticipated to grow from 87.0 million USD in 2024 to 196.7 million USD by 2035.
Leading companies partner with us for data-driven Insights.
Kindly complete the form below to receive a free sample of this Report
Assistant Manager He holds an experience of about 7+ years in market research and business consulting, working under the spectrum of life sciences and healthcare domains. rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. his expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc. in addition to the above, his other responsibility includes strategic tracking of high growth markets & advising clients on the potential areas of focus they could direct their business initiatives
Get in Touch
© 2025 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)
